Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
FENTANYL-100 vs ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Fentanyl is a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system, activating G-protein coupled receptor signaling (inhibition of adenylate cyclase, modulation of ion channels), leading to increased potassium conductance and decreased calcium influx, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.
Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Management of pain in opioid-tolerant patients requiring around-the-clock opioid analgesia for severe chronic pain,Anesthesia (adjunct to general or regional anesthesia),Procedural sedation,Patient-controlled analgesia (PCA),Breakthrough pain management (off-label use)
Mild to moderate pain,Fever (acetaminophen and aspirin),Inflammatory conditions (aspirin)
100 mcg intravenously every 1-2 hours as needed for pain; or 100 mcg intramuscularly every 1-2 hours; transdermal patch: 12-100 mcg/hour applied every 72 hours; buccal tablet: 100-200 mcg as a single dose for breakthrough pain.
1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.
Terminal elimination half-life: 2–4 hours in adults; prolonged in elderly, hepatic impairment, or continuous infusion (due to redistribution).
Acetaminophen: 2-3 hours (terminal). Aspirin: 15-30 minutes (parent drug); salicylate: 2-3 hours at low doses, 15-30 hours at high doses due to saturable metabolism. Codeine: 2.5-4 hours. Clinical context: Prolonged half-life of salicylate at high doses increases risk of toxicity; hepatic impairment prolongs acetaminophen and codeine half-lives.
Primarily hepatic via CYP3A4, with minor contribution from CYP3A5. Major metabolites: norfentanyl (inactive), despropionylfentanyl. Approximately 10-25% excreted unchanged in urine.
Acetaminophen: hepatic via CYP2E1, CYP1A2, CYP3A4; glucuronidation and sulfation; NAPQI formation. Aspirin: hepatic hydrolysis to salicylate; conjugation with glycine and glucuronic acid. Codeine: hepatic via CYP2D6 to morphine (active); also via CYP3A4 to norcodeine.
Primarily hepatic metabolism to inactive metabolites (norfentanyl, etc.); ~75% excreted in urine as metabolites, ~9% in feces, <10% unchanged in urine.
Acetaminophen: renal excretion of metabolites (glucuronide and sulfate conjugates, ~85-90%), minor parent drug (<5%). Aspirin: renal excretion of salicylate and its metabolites (salicyluric acid, glucuronides, gentisic acid), dose-dependent; at therapeutic doses, ~50-80% as free salicylate and conjugates. Codeine: renal excretion of free and conjugated codeine (about 90%) and metabolites (morphine, norcodeine).
~80–85% bound, primarily to albumin and alpha-1-acid glycoprotein.
Acetaminophen: 10-25% (albumin). Aspirin: 50-80% (albumin), dose-dependent; salicylate: 75-90% (albumin). Codeine: ~7% (albumin).
3–8 L/kg (large Vd indicates extensive tissue distribution, especially to fat and muscle).
Acetaminophen: 0.9-1.0 L/kg (large distribution including liver). Aspirin: 0.15-0.2 L/kg (low Vd, confined to plasma and extracellular fluid); salicylate: 0.2-0.3 L/kg. Codeine: 3-6 L/kg (extensive tissue distribution). Clinical meaning: Large Vd for codeine suggests extensive tissue binding; aspirin Vd is small, consistent with limited extravascular distribution.
Oral: <40% (first-pass metabolism); Buccal: ~50%; Intranasal: 50–90%; Transdermal: ~30–60% (steady state).
Oral: Acetaminophen: 85-95%. Aspirin: 40-60% (due to first-pass hydrolysis to salicylate). Codeine: ~50% due to first-pass metabolism.
GFR 30-50 m L/min: reduce dose by 25-50%; GFR 10-29 m L/min: reduce dose by 50-75% and extend dosing interval; GFR <10 m L/min: use with caution, consider alternative therapy; not removed by hemodialysis.
GFR 30-59 m L/min: Administer every 6 hours; maximum 6 tablets/day. GFR 15-29 m L/min: Administer every 12 hours; maximum 4 tablets/day. GFR <15 m L/min: Not recommended due to accumulation of codeine metabolites.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: reduce dose by 75% or use alternative; monitor for respiratory depression.
Child-Pugh Class A: No adjustment. Child-Pugh Class B: Reduce dose by 50% and extend interval to every 6 hours; maximum 4 tablets/day. Child-Pugh Class C: Contraindicated.
Intravenous: 0.5-2 mcg/kg/dose every 2-4 hours; transmucosal: 5-15 mcg/kg for procedural analgesia; transdermal patch: not recommended in children <2 years; in older children, use lowest effective dose based on body weight and opioid tolerance.
Not recommended for children <12 years due to aspirin risk of Reye syndrome. For children ≥12 years: Dose based on codeine component (0.5-1 mg/kg/dose) with maximum acetaminophen 75 mg/kg/day and aspirin 100 mg/kg/day. Typical: 1 tablet (acetaminophen 300 mg/aspirin 300 mg/codeine 30 mg) every 4-6 hours as needed; max 4 tablets/day.
Start at 25-50% of adult dose; titrate slowly; avoid transdermal patch in opioid-naive elderly; monitor for delirium and respiratory depression; prefer intravenous or buccal routes with careful observation.
Start with lowest effective dose (e.g., 1 tablet every 6 hours); monitor renal and hepatic function; maximum 6 tablets/day due to increased sensitivity and risk of adverse effects.
Risk of respiratory depression, which may be fatal, especially in opioid-naive patients and when used in higher doses or with other CNS depressants. Risk of accidental exposure leading to fatal overdose. Risk of abuse, misuse, addiction, and diversion. Concomitant use with benzodiazepines or other CNS depressants may result in profound sedation, respiratory depression, coma, and death. Avoid use in patients with known or suspected paralytic ileus. Use only in opioid-tolerant patients for outpatient chronic pain management.
Risk of medication errors: confusion between different strengths and concentrations of acetaminophen can result in accidental overdose and fatal hepatotoxicity. Aspirin use in children and teenagers with viral infections is associated with Reye's syndrome.
Respiratory depression: monitor closely, especially during initiation and dose titration. Abuse and addiction potential: fentanyl is a Schedule II controlled substance. Life-threatening respiratory depression with concurrent use of benzodiazepines or CNS depressants. Serotonin syndrome when coadministered with serotonergic drugs. Adrenal insufficiency. Severe hypotension, including orthostatic hypotension. Risk of seizures in patients with seizure disorders. Avoid use in patients with head injury or increased intracranial pressure. Biliary tract spasm. Use in pregnancy may cause neonatal opioid withdrawal syndrome. Avoid abrupt discontinuation to prevent withdrawal. Must be used only in opioid-tolerant patients for outpatient management.
Hepatotoxicity (acetaminophen dose >4 g/day), Reye's syndrome (aspirin in children), respiratory depression (codeine), tolerance/dependence, bleeding risk (aspirin), GI toxicity, renal impairment, hypersensitivity reactions.
Hypersensitivity to fentanyl or any component of the product, significant respiratory depression, acute or severe bronchial asthma in an unmonitored setting, known or suspected gastrointestinal obstruction (including paralytic ileus), concurrent use of monoamine oxidase inhibitors (MAOIs) or within 14 days of stopping such therapy.
Hypersensitivity to any component, active peptic ulcer disease, bleeding disorders, severe hepatic impairment, severe respiratory depression, children with viral illness (aspirin), pregnancy (third trimester for aspirin, codeine cautious).
Avoid or limit alcohol and grapefruit juice as they can potentiate respiratory depression and alter fentanyl metabolism. Maintain adequate hydration and fiber intake to prevent constipation.
Avoid alcohol due to increased risk of acetaminophen hepatotoxicity and aspirin-induced GI bleeding. Avoid large amounts of caffeine or high-tyramine foods (e.g., aged cheeses, cured meats) as they may affect CYP2D6 metabolism of codeine.
FDA Pregnancy Category C. First trimester: Limited human data; animal studies show teratogenic effects at high doses. Second and third trimesters: Chronic use may lead to neonatal opioid withdrawal syndrome; no structural malformations reported at therapeutic doses.
Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastroschisis; second trimester: relatively safe; third trimester: risk of premature closure of ductus arteriosus, oligohydramnios, and increased peripartum hemorrhage. Codeine: First trimester: possible neural tube defects; second and third trimesters: risk of respiratory depression, withdrawal in neonate with chronic use; neonatal opioid withdrawal syndrome (NOWS) possible.
Fentanyl is excreted into breast milk in low concentrations; M/P ratio is approximately 0.4. Limited data suggest minimal risk at maternal doses; however, monitor infant for signs of sedation or respiratory depression. Avoid use with breastfeeding for 24 hours after administration due to long half-life.
Acetaminophen: M/P ratio approximately 0.91-1.42; considered safe. Aspirin: M/P ratio 0.08-0.15; high doses may cause Reye's syndrome; avoid or use low doses. Codeine: M/P ratio about 2.5; variable metabolism; risk of CNS depression in infant; avoid due to potential for toxicity in CYP2D6 ultrarapid metabolizers.
No specific dose adjustment required for acute pain; however, increased clearance in late pregnancy may necessitate higher doses for chronic pain. Use lowest effective dose for shortest duration to minimize neonatal withdrawal risk.
Acetaminophen: No dose adjustment needed. Aspirin: Avoid in third trimester; use lowest effective dose if necessary. Codeine: Avoid in pregnancy; if used, lowest effective dose for shortest duration; caution for CYP2D6 polymorphism. Pharmacokinetic changes: Increased clearance of codeine during pregnancy may require higher doses but risk outweighs benefit.
FENTANYL-100 transdermal patch is indicated only for opioid-tolerant patients with chronic pain requiring around-the-clock analgesia. Apply to non-irritated, non-hairy skin on upper torso or inner forearm; avoid heating pads, saunas, or sun exposure that increase absorption. Monitor for respiratory depression, especially in opioid-naive patients. Patches should be replaced every 72 hours; do not cut or damage the patch. Dispose of used patches by folding adhesive sides together and flushing down toilet.
Combination analgesic with acetaminophen (hepatotoxic at high doses), aspirin (antiplatelet, GI irritant, contraindicated in children <12 due to Reye's syndrome), and codeine (prodrug to morphine via CYP2D6; efficacy depends on CYP2D6 phenotype; risk of CNS/respiratory depression). Avoid in severe hepatic/renal impairment, active peptic ulcer, bleeding disorders, or concomitant use of other CNS depressants. Maximum acetaminophen dose from all sources: 4 g/day.
Apply the patch to clean, dry, hairless skin and press firmly for 30 seconds.,Do not expose the patch to direct heat sources (heating pads, hot tubs, electric blankets).,Keep away from children and pets; used patches must be flushed down toilet.,Do not drink alcohol or take other central nervous system depressants without consulting your doctor.,Report any difficulty breathing, extreme drowsiness, or confusion immediately.
Do not exceed recommended dose; acetaminophen overdosage can cause serious liver damage.,Do not take with other products containing acetaminophen or aspirin.,Avoid alcohol while taking this medication to reduce risk of liver toxicity and GI bleeding.,This product contains aspirin; do not give to children/teenagers with chickenpox or flu-like symptoms to avoid Reye's syndrome.,May cause drowsiness; do not drive or operate machinery until you know how you react.,Codeine is a narcotic pain reliever with abuse potential; use exactly as prescribed.,Seek medical attention if you experience signs of allergic reaction (rash, difficulty breathing) or bleeding (black/tarry stools, unusual bruising).
"Metaraminol, a direct-acting alpha-adrenergic agonist, can reduce the serum concentration of fentanyl, a potent opioid analgesic, likely through enhanced hepatic metabolism or altered renal clearance. This interaction may lead to diminished analgesic efficacy of fentanyl, requiring higher doses to achieve pain control and potentially increasing the risk of opioid withdrawal symptoms. Clinically, patients receiving both drugs may exhibit inadequate pain relief or unexpected opioid tolerance."
"The concomitant use of pergolide, a dopamine receptor agonist, and fentanyl, a μ-opioid receptor agonist, may result in additive central nervous system depression, leading to increased sedation, respiratory depression, and potential for coma or death. Pergolide can also potentiate the hypotensive effects of opioids, resulting in orthostatic hypotension and syncope. Additionally, both drugs can prolong the QTc interval, increasing the risk of torsades de pointes and sudden cardiac death."
"The combination of glycopyrronium, an anticholinergic agent, and fentanyl, a potent mu-opioid receptor agonist, can result in additive anticholinergic effects, specifically severe constipation, urinary retention, and central nervous system depression, leading to delirium or cognitive impairment in susceptible patients. Additionally, fentanyl-induced gastrointestinal hypomotility is exacerbated by glycopyrronium, increasing the risk of paralytic ileus. Clinically, patients may present with prolonged QTc interval, decreased gastrointestinal motility, and exacerbated sedation, particularly in elderly or renally impaired individuals."
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about FENTANYL-100 vs ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE, answered by our medical review team.
FENTANYL-100 is a Opioid Agonist that works by Fentanyl is a μ-opioid receptor agonist. It binds to μ-opioid receptors in the central nervous system, activating G-protein coupled receptor signaling (inhibition of adenylate cyclase, modulation of ion channels), leading to increased potassium conductance and decreased calcium influx, resulting in hyperpolarization and reduced neurotransmitter release. This produces analgesia, sedation, and respiratory depression.. ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: cyclooxygenase (COX) inhibitor, primarily central, analgesic and antipyretic. Aspirin: irreversible COX-1 and COX-2 inhibitor, analgesic, anti-inflammatory, antipyretic, antiplatelet. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between FENTANYL-100 and ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of FENTANYL-100 is: 100 mcg intravenously every 1-2 hours as needed for pain; or 100 mcg intramuscularly every 1-2 hours; transdermal patch: 12-100 mcg/hour applied every 72 hours; buccal tablet: 100-200 mcg as a single dose for breakthrough pain.. The standard adult dose of ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is: 1-2 tablets (each containing acetaminophen 300 mg, aspirin 300 mg, codeine phosphate 30 mg) orally every 4-6 hours as needed for pain; maximum 8 tablets/day.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining FENTANYL-100 and ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE. The risk or severity of adverse effects can be increased when Codeine is combined with Fentanyl. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. FENTANYL-100 is classified as Category D/X. FDA Pregnancy Category C. First trimester: Limited human data; animal studies show teratogenic effects at high doses. Second and third trimesters: Chronic use may lead to neonatal . ACETAMINOPHEN, ASPIRIN, AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen: Generally considered low risk; association with ASD and ADHD with prolonged use not fully established. Aspirin: First trimester: possible increased risk of gastrosch. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.